Related Experiment Videos
Novel investigative approaches for advanced renal cell carcinoma
W J Berg1, C R Divgi, D M Nanus
1Department of Nuclear Medicine, Weill Medical College of Cornell University, New York, NY, USA.
Abstract:
Metastatic renal cell carcinoma remains one of the most treatment-resistant malignancies in humans. As such, long-term survival is limited to a minority of patients. Interferon-alpha and interleukin-2 induced major responses in some patients with renal cell carcinoma, and in so doing generated a great deal of interest and hope. However, clinical benefit is limited to relatively few patients. Here, we briefly discuss the management of metastatic renal cell carcinoma, and then elaborate on several novel treatment approaches in development, including retinoids, monoclonal antibodies, and antiangiogenesis strategies.
Insights
Metastatic renal cell carcinoma is difficult to treat, with limited long-term survival. Novel therapies like retinoids, monoclonal antibodies, and antiangiogenesis strategies show promise for improving outcomes in this resistant cancer.
Area of Science:
- Oncology
- Cancer Research
Background:
- Metastatic renal cell carcinoma (RCC) is a highly treatment-resistant human malignancy.
- Current treatment options offer limited long-term survival for most patients.
- While therapies like interferon-alpha and interleukin-2 have shown some success, their clinical benefit is restricted to a small patient subset.
Purpose of the Study:
- To review the current management strategies for metastatic renal cell carcinoma.
- To explore emerging novel treatment modalities for metastatic renal cell carcinoma.
- To discuss the potential of retinoids, monoclonal antibodies, and antiangiogenesis strategies in advanced RCC treatment.
Main Methods:
- Literature review of current metastatic renal cell carcinoma management.
- Discussion of ongoing clinical development of novel therapeutic agents.
- Analysis of the mechanisms and potential applications of retinoids, monoclonal antibodies, and antiangiogenesis in RCC.
Main Results:
- Metastatic renal cell carcinoma presents significant therapeutic challenges.
- Established treatments provide limited efficacy for the majority of patients.
- Novel approaches are under investigation to overcome treatment resistance.
Conclusions:
- The management of metastatic renal cell carcinoma requires innovative therapeutic strategies.
- Emerging treatments, including retinoids, monoclonal antibodies, and antiangiogenesis, offer new hope.
- Further research and clinical trials are essential to evaluate the efficacy of these novel approaches in improving patient survival and outcomes.